A Phase 1/2 interventional study of K-1728 and Fulvestrant in Breast Neoplasms, Solid Tumors and PIK3CA Gene Mutation, sponsored by KymaThera, Inc.. Recruiting at 2 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by KymaThera, Inc. · Phase 1/2, Interventional, and Treatment
How we know · 8 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 403 studies in Breast Neoplasms with a site in Australia — 85 open to participants now, 156 under way, 61 of them phase 3. Breast Neoplasms · Australia.
Among the 403 studies in Breast Neoplasms with a site in Australia, this one is the 265th largest by planned enrollment of the 381 interventional ones that give a count, is one of 17 that started in 2026, is one of 42 in phase 1/2, reaches primary completion later than 113 of the 155 other live ones, and was the 402nd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →85 of the 403 studies in Breast Neoplasms with a site in Australia are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Australia, Japan
Ages 18+
Antares Therapeutics, Inc · Sites in Australia, United States
Ages 18+
Second Life Therapeutics · Sites in Australia
Ages 18+
Alpha-9 Oncology USA Inc. · Sites in Australia
Ages 18+
Novartis Pharmaceuticals · Sites in Australia, United States, Canada and 1 more country
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
403 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 114 · Phase 2 125 · Phase 3 158 · Phase 4 4
First in 1993; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 252 across the 381 interventional studies, 798 across the 19 observational. Of the 231 that completed or were terminated, 137 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
316 of 403 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with KymaThera, Inc. as lead sponsor.
KymaThera, Inc. has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
44 of the studies in Breast Neoplasms with a site in Australia that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT04873362Phase 3Hoffmann-La RocheA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy | 2027-03-31 |
| NCT05696626Phase 3LeonaBioEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | 2027-04 |
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT05894239Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | 2027-05-03 |
Add all 44 to your calendar (.ics) → With an account.
Among the 403 studies in Breast Neoplasms with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This first-in-human, open-label, multicenter study evaluates K-1728 administered as monotherapy and in combination in participants with advanced or metastatic solid tumors. The study assesses the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of K-1728.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive K-1728 orally as monotherapy
Drug: K-1728
Participants receive K-1728 orally in combination with endocrine therapy
Drug: K-1728 · Drug: Fulvestrant
Participants receive K-1728 orally in combination with endocrine therapy and a CDK4/6 inhibitor
Drug: K-1728 · Drug: Fulvestrant · Drug: Palbociclib
K-1728 will be administered orally once daily in 28-day cycles
Fulvestrant will be administered intramuscularly on Days 1 and 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle
Palbociclib will be administered orally on Days 1-21 in 28-day cycles
Maximum Tolerated Dose (MTD)/Maximum Efficacious Dose (MED) and Recommended Phase 2 Dose (RP2D)
Determination of the MTD/MED and RP2D of K-1728 administered as monotherapy and in combination
Time frame: Cycle 1 (28 days) through completion of dose escalation (up to approximately 24 months)
Incidence of Dose-Limiting Toxicities (DLTs)
Number and percentage of participants experiencing a dose-limiting toxicity during the DLT-evaluation period with of K-1728 administered as monotherapy and in combination
Time frame: Initiation of study drug through Cycle 1 (28 days)
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number and percentage of participants with adverse events and serious adverse events with K-1728 administered as a monotherapy and in combination
Time frame: From first dose through 30 days after the last dose of study treatment (up to approximately 24 months)
Changes in laboratory parameters
Compared to baseline, changes in laboratory parameters with K-1728 administered as monotherapy and in combination
Time frame: From first dose through 30 days after the last dose of study treatment (up to approximately 24 months)
Changes in vital signs
Compared to baseline, changes in vital signs with K-1728 administered as monotherapy and in combination
Time frame: From first dose through 30 days after the last dose of study treatment (up to approximately 24 months)
Changes in electrocardiogram (ECG) parameters
Compared to baseline, changes in ECG parameters (including QT interval, QTc interval, QRS complex, and PR interval)
Time frame: From first dose through 30 days after the last dose of study treatment (up to approximately 24 months)
Changes in physical examination
Compared to baseline, changes in physical examination
Time frame: From first dose through 30 days after the last dose of study treatment (up to approximately 24 months)
Pharmacokinetics - Maximum Plasma Concentration (Cmax) of K-1728
Cmax of K-1728 when administered as monotherapy or in combination
Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle until end of treatment, approximately 24 months
Pharmacokinetics - Time to Maximum Plasma Concentration (Tmax) of K-1728
Tmax of K-1728 when administered as monotherapy or in combination
Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle until end of treatment, approximately 24 months
Pharmacokinetics - Area Under the Plasma Concentration-Time Curve (AUC) of K-1728
AUC of K-1728 when administered as monotherapy or in combination
Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle until end of treatment, approximately 24 months
Pharmacokinetics - Half-life (t1/2) of K-1728 when administered as monotherapy or in combination
t1/2 of K-1728 when administered as monotherapy or in combination
Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle until end of treatment, approximately 24 months
Preliminary Efficacy - Overall Response Rate (ORR)
Objective Response Rate (ORR) as assessed by RECIST v1.1
Time frame: Initiation of study drug until disease progression, assessed up to approximately 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Sep 2028, 23 months after the start.
Of 164 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 23 months is below that.
Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.